Susan Faye Dent
Professor of Medicine
Medical Oncologist with a focus on breast cancer
Associate Director of Breast Cancer Clinical Research
Co-Director Duke Cardio-Oncology Program
Associate Director of Breast Cancer Clinical Research
Co-Director Duke Cardio-Oncology Program
Current Appointments & Affiliations
- Professor of Medicine, Medicine, Medical Oncology, Medicine 2021
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2019
Contact Information
- DUMC 3446, Durham, NC 27710
- DUMC 3446, Durham, NC 27710
-
susan.dent@duke.edu
(919) 684-5734
- Background
-
Education, Training, & Certifications
- Medical Oncology, Royal College of Physicians (United Kingdom) 1993 - 1995
- Internal Medicine, Royal College of Physicians (United Kingdom) 1990 - 1993
- M.D., McMaster University (Canada) 1990
-
Previous Appointments & Affiliations
- Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2018 - 2021
- Research
-
Selected Grants
- A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) awarded by AstraZeneca AB 2022 - 2027
- Preventing Inflammatory Breast Cancer Metastases by Interrupting Cellular Stress Signaling in Lymphatic Emboli and Circulating Tumor Cell Clusters awarded by Department of Defense 2020 - 2023
- Cardiovascular Impact of Near-complete Estrogen Deprivation for Breast Cancer awarded by Wake Forest University School Of Medicine 2022 - 2023
- CardiovAscular Risk profile and Treatment patterns in ER+HER2 - Advanced Breast Cancer: A retrospective cohort study (CAREB) awarded by Novartis Pharmaceuticals Corporation 2019 - 2022
- A PHASEIB/III STUDY OF IPATASERTIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN HORMONE RECEPTOR POSITIVE AND HER2 NEGATIVE LOCALLY ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER awarded by F. Hoffmann-La Roche Ltd 2019 - 2022
- Translational Breast Cancer Research Consortium 2021 Infrastructure (BCRF) awarded by Susan G. Komen Breast Cancer Foundation 2021 - 2022
- Translational Breast Cancer Research Consortium 2021 Infrastructure - SGK awarded by Susan G. Komen Breast Cancer Foundation 2021 - 2022
-
External Relationships
- Myocardial Solutions
- Novartis pharmaceuticals
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Guha, Avirup, Yan Gong, David DeRemer, Jocelyn Owusu-Guha, Susan F. Dent, Richard K. Cheng, Neal L. Weintraub, Neeraj Agarwal, and Michael G. Fradley. “Cardiometabolic Consequences of Targeted Anticancer Therapies.” J Cardiovasc Pharmacol 80, no. 4 (October 1, 2022): 515–21. https://doi.org/10.1097/FJC.0000000000001149.Full Text Link to Item
-
Porter, Charles, Tariq U. Azam, Divyanshu Mohananey, Rohit Kumar, Jian Chu, Daniel Lenihan, Susan Dent, Sarju Ganatra, Gary S. Beasley, and Tochukwu Okwuosa. “Permissive Cardiotoxicity: The Clinical Crucible of Cardio-Oncology.” Jacc Cardiooncol 4, no. 3 (September 2022): 302–12. https://doi.org/10.1016/j.jaccao.2022.07.005.Full Text Link to Item
-
Zullig, Leah L., Anthony D. Sung, Michel G. Khouri, Shelley Jazowski, Nishant P. Shah, Andrea Sitlinger, Dan V. Blalock, et al. “Cardiometabolic Comorbidities in Cancer Survivors: JACC: CardioOncology State-of-the-Art Review.” Jacc Cardiooncol 4, no. 2 (June 2022): 149–65. https://doi.org/10.1016/j.jaccao.2022.03.005.Full Text Open Access Copy Link to Item
-
Al-Tweigeri, Taher, Susan Dent, Adher Al Sayed, Dania Mohty, Kausar Suleman, Dahish Ajarim, Hussein Raef, and Najmeddine Echahidi. “Using the Appropriate Formula for QT Measurement Can Save Lives.” Hematol Oncol Stem Cell Ther 15, no. 1 (March 1, 2022): 79–82. https://doi.org/10.1016/j.hemonc.2021.06.001.Full Text Link to Item
-
Blaes, A. H., S. Konety, J. Hui, K. Dusenbery, J. Yuan, S. Dent, K. C. Oeffinger, and L. M. Turcotte. “How to Treat Breast Cancer After Childhood Cancer: Management of Oncologic and Cardiovascular Concerns.” Jacc: Cardiooncology 4, no. 1 (March 1, 2022): 126–29. https://doi.org/10.1016/j.jaccao.2021.12.003.Full Text
-
Guha, Avirup, Michael G. Fradley, Susan F. Dent, Neal L. Weintraub, Maryam B. Lustberg, Alvaro Alonso, and Daniel Addison. “Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis.” Eur Heart J 43, no. 4 (January 31, 2022): 300–312. https://doi.org/10.1093/eurheartj/ehab745.Full Text Link to Item
-
Herrmann, Joerg, Daniel Lenihan, Saro Armenian, Ana Barac, Anne Blaes, Daniela Cardinale, Joseph Carver, et al. “Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.” Eur Heart J 43, no. 4 (January 31, 2022): 280–99. https://doi.org/10.1093/eurheartj/ehab674.Full Text Link to Item
-
De Laurentiis, Michelino, Simona Borstnar, Mario Campone, Ellen Warner, Javier Salvador Bofill, William Jacot, Susan Dent, et al. “Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.” Breast Cancer Res Treat 191, no. 1 (January 2022): 223–24. https://doi.org/10.1007/s10549-021-06374-6.Full Text Link to Item
-
Krzyzanowska, Monika K., Jim A. Julian, Chu-Shu Gu, Melanie Powis, Qing Li, Katherine Enright, Doris Howell, et al. “Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial.” Bmj 375 (December 8, 2021): e066588. https://doi.org/10.1136/bmj-2021-066588.Full Text Link to Item
-
Lopez-Mattei, J. C., E. H. Yang, M. Ferencik, L. A. Baldassarre, S. Dent, and M. J. Budoff. “Cardiac Computed Tomography in Cardio-Oncology: JACC: CardioOncology Primer.” Jacc: Cardiooncology 3, no. 5 (December 1, 2021): 635–49. https://doi.org/10.1016/j.jaccao.2021.09.010.Full Text
-
Zullig, Leah L., Mohammad Shahsahebi, Benjamin Neely, Terry Hyslop, Renee A. V. Avecilla, Brittany M. Griffin, Kacey Clayton-Stiglbauer, et al. “Low-touch, team-based care for co-morbidity management in cancer patients: the ONE TEAM randomized controlled trial.” Bmc Fam Pract 22, no. 1 (November 18, 2021): 234. https://doi.org/10.1186/s12875-021-01569-8.Full Text Link to Item
-
Alhussein, M. M., A. Mokbel, T. Cosman, N. Aghel, E. H. Yang, S. D. Mukherjee, S. Dent, P. M. Ellis, S. Dhesy-Thind, and D. P. Leong. “Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis.” Cjc Open 3, no. 11 (November 1, 2021): 1372–82. https://doi.org/10.1016/j.cjco.2021.06.019.Full Text
-
Geršak, B. M., A. Kukec, H. Steen, M. Montenbruck, M. Šoštarič, A. K. Schwarz, S. Esch, et al. “Povezanost med kazalniki kakovosti življenja ter kazalniki srčnega statusa pri bolnikih, ki prejemajo kemoterapijo.” Zdravstveno Varstvo 60, no. 4 (October 20, 2021): 199–209. https://doi.org/10.2478/sjph-2021-0028.Full Text
-
De Laurentiis, Michelino, Simona Borstnar, Mario Campone, Ellen Warner, Javier Salvador Bofill, William Jacot, Susan Dent, et al. “Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.” Breast Cancer Research and Treatment 189, no. 3 (October 2021): 689–99. https://doi.org/10.1007/s10549-021-06334-0.Full Text
-
Mitchell, Joshua D., Daniel A. Cehic, Marita Morgia, Carmen Bergom, Joanne Toohey, Patricia A. Guerrero, Maros Ferencik, et al. “Cardiovascular Manifestations From Therapeutic Radiation: A Multidisciplinary Expert Consensus Statement From the International Cardio-Oncology Society.” Jacc Cardiooncol 3, no. 3 (September 2021): 360–80. https://doi.org/10.1016/j.jaccao.2021.06.003.Full Text Link to Item
-
Dent, Susan F., Amber Morse, Sarah Burnette, Avirup Guha, and Heather Moore. “Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer.” Curr Oncol Rep 23, no. 11 (August 27, 2021): 128. https://doi.org/10.1007/s11912-021-01114-x.Full Text Link to Item
-
Fradley, Michael G., Theresa M. Beckie, Sherry Ann Brown, Richard K. Cheng, Susan F. Dent, Anju Nohria, Kristen K. Patton, Jagmeet P. Singh, and Brian Olshansky. “Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A Scientific Statement From the American Heart Association.” Circulation 144, no. 3 (July 20, 2021): e41–55. https://doi.org/10.1161/CIR.0000000000000986.Full Text Link to Item
-
Kwan, Jennifer M., Mariana L. Henry, Briana Christophers, Kamala Tamirisa, Ritu Thamman, Diego Sadler, Niti R. Aggarwal, et al. “The Role and Impact of Social Media in Cardio-oncology During the COVID-19 Pandemic.” Current Oncology Reports 23, no. 8 (July 2021): 99. https://doi.org/10.1007/s11912-021-01081-3.Full Text
-
Giusca, Sorin, Grigorios Korosoglou, Moritz Montenbruck, Blaž Geršak, Arne Kristian Schwarz, Sebastian Esch, Sebastian Kelle, et al. “Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up.” Circ Cardiovasc Imaging 14, no. 6 (June 2021): e012459. https://doi.org/10.1161/CIRCIMAGING.121.012459.Full Text Link to Item
-
Rao, Vijay U., David J. Reeves, Atul R. Chugh, Rupal O’Quinn, Michael G. Fradley, Meghana Raghavendra, Susan Dent, Ana Barac, and Daniel Lenihan. “Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents: JACC State-of-the-Art Review.” J Am Coll Cardiol 77, no. 21 (June 1, 2021): 2693–2716. https://doi.org/10.1016/j.jacc.2021.04.009.Full Text Link to Item
-
Baldassarre, Lauren A., Eric H. Yang, Richard K. Cheng, Jeanne M. DeCara, Susan Dent, Jennifer E. Liu, Lawrence G. Rudski, et al. “Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils.” J Natl Cancer Inst 113, no. 5 (May 4, 2021): 513–22. https://doi.org/10.1093/jnci/djaa177.Full Text Link to Item
-
Piccart, Martine, Marion Procter, Debora Fumagalli, Evandro de Azambuja, Emma Clark, Michael S. Ewer, Eleonora Restuccia, et al. “Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.” J Clin Oncol 39, no. 13 (May 1, 2021): 1448–57. https://doi.org/10.1200/JCO.20.01204.Full Text Link to Item
-
Dent, S., J. Cortés, Y. -. H. Im, V. Diéras, N. Harbeck, I. E. Krop, T. R. Wilson, et al. “Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.” Ann Oncol 32, no. 2 (February 2021): 197–207. https://doi.org/10.1016/j.annonc.2020.10.596.Full Text Link to Item
-
Dent, S. F., J. Botros, M. Rushton, O. Aseyev, M. N. Levine, W. R. Parulekar, P. O’Brien, et al. “Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience.” Breast Cancer Res Treat 184, no. 3 (December 2020): 733–41. https://doi.org/10.1007/s10549-020-05887-w.Full Text Link to Item
-
Sadler, Diego, Jeanne M. DeCara, Joerg Herrmann, Anita Arnold, Arjun K. Ghosh, Husam Abdel-Qadir, Eric H. Yang, et al. “Perspectives on the COVID-19 pandemic impact on cardio-oncology: results from the COVID-19 International Collaborative Network survey.” Cardiooncology 6, no. 1 (November 27, 2020): 28. https://doi.org/10.1186/s40959-020-00085-5.Full Text Link to Item
-
Alvarez-Cardona, Jose A., Jordan Ray, Joseph Carver, Vlad Zaha, Richard Cheng, Eric Yang, Joshua D. Mitchell, et al. “Cardio-Oncology Education and Training: JACC Council Perspectives.” J Am Coll Cardiol 76, no. 19 (November 10, 2020): 2267–81. https://doi.org/10.1016/j.jacc.2020.08.079.Full Text Link to Item
-
Lenihan, Daniel, Joseph Carver, Charles Porter, Jennifer E. Liu, Susan Dent, Paaladinesh Thavendiranathan, Joshua D. Mitchell, et al. “Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement.” Ca Cancer J Clin 70, no. 6 (November 2020): 480–504. https://doi.org/10.3322/caac.21635.Full Text Link to Item
-
Lyon, Alexander R., Susan Dent, Susannah Stanway, Helena Earl, Christine Brezden-Masley, Alain Cohen-Solal, Carlo G. Tocchetti, et al. “Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.” Eur J Heart Fail 22, no. 11 (November 2020): 1945–60. https://doi.org/10.1002/ejhf.1920.Full Text Link to Item
-
Pudil, Radek, Christian Mueller, Jelena Čelutkienė, Peter A. Henriksen, Dan Lenihan, Susan Dent, Ana Barac, et al. “Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.” Eur J Heart Fail 22, no. 11 (November 2020): 1966–83. https://doi.org/10.1002/ejhf.2017.Full Text Link to Item
-
Addison, Daniel, Courtney M. Campbell, Avirup Guha, Arjun K. Ghosh, Susan F. Dent, and Hani Jneid. “Cardio-Oncology in the Era of the COVID-19 Pandemic and Beyond.” J Am Heart Assoc 9, no. 19 (October 20, 2020): e017787. https://doi.org/10.1161/JAHA.120.017787.Full Text Link to Item
-
Kikuchi, Robin, Nishant P. Shah, and Susan F. Dent. “Strategies to Prevent Cardiovascular Toxicity in Breast Cancer: Is It Ready for Primetime?” J Clin Med 9, no. 4 (March 25, 2020). https://doi.org/10.3390/jcm9040896.Full Text Open Access Copy Link to Item
-
Dent, Susan F., Robin Kikuchi, Lavanya Kondapalli, Roohi Ismail-Khan, Christine Brezden-Masley, Ana Barac, and Michael Fradley. “Optimizing Cardiovascular Health in Patients With Cancer: A Practical Review of Risk Assessment, Monitoring, and Prevention of Cancer Treatment-Related Cardiovascular Toxicity.” Am Soc Clin Oncol Educ Book 40 (March 2020): 1–15. https://doi.org/10.1200/EDBK_286019.Full Text Link to Item
-
Sammons, Sarah, Mythili Shastry, Susan Dent, Carey Anders, and Erika Hamilton. “Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2- Breast Cancer.” Clin Breast Cancer 20, no. 1 (February 2020): 1–11. https://doi.org/10.1016/j.clbc.2019.06.017.Full Text Link to Item
-
Curigliano, G., D. Lenihan, M. Fradley, S. Ganatra, A. Barac, A. Blaes, J. Herrmann, et al. “Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.” Ann Oncol 31, no. 2 (February 2020): 171–90. https://doi.org/10.1016/j.annonc.2019.10.023.Full Text Link to Item
-
Dent, Susan F., Thomas M. Suter, Teresa López-Fernández, Grzegorz Opolski, Pierantonio Menna, and Giorgio Minotti. “Cardio-oncology in clinical studies and real life.” Semin Oncol 46, no. 6 (December 2019): 421–25. https://doi.org/10.1053/j.seminoncol.2019.01.004.Full Text Link to Item
-
Lenihan, Daniel J., Michael G. Fradley, Susan Dent, Christine Brezden-Masley, Joseph Carver, Roberto Kalil Filho, Tomas G. Neilan, et al. “Proceedings From the Global Cardio-Oncology Summit: The Top 10 Priorities to Actualize for CardioOncology.” Jacc Cardiooncol 1, no. 2 (December 2019): 256–72. https://doi.org/10.1016/j.jaccao.2019.11.007.Full Text Link to Item
-
Phillips, William J., Christopher Johnson, Angeline Law, Michele Turek, Alex R. Small, Susan Dent, Terrence D. Ruddy, Rob S. Beanlands, Benjamin J. W. Chow, and Gary R. Small. “Comparison of Framingham risk score and chest-CT identified coronary artery calcification in breast cancer patients to predict cardiovascular events.” International Journal of Cardiology 289 (August 2019): 138–43. https://doi.org/10.1016/j.ijcard.2019.01.056.Full Text
-
Dent, Susan, Chiara Melloni, Josee Ivars, Sarah Sammons, and Gretchen Kimmick. “Cardiotoxicities of Modern Treatments in Breast Cancer.” Curr Treat Options Cardiovasc Med 21, no. 7 (June 15, 2019): 34. https://doi.org/10.1007/s11936-019-0738-z.Full Text Link to Item
-
Kappel, C., M. Rushton, C. Johnson, O. Aseyev, G. Small, A. Law, J. Ivars, and S. Dent. “Clinical experience of patients referred to a multidisciplinary cardio-oncology clinic: an observational cohort study.” Curr Oncol 26, no. 3 (June 2019): e322–27. https://doi.org/10.3747/co.26.4509.Full Text Link to Item
-
Kosalka, P., C. Johnson, M. Turek, J. Sulpher, A. Law, J. Botros, S. Dent, and O. Aseyev. “Effect of obesity, dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in breast cancer.” Curr Oncol 26, no. 3 (June 2019): e314–21. https://doi.org/10.3747/co.26.4823.Full Text Link to Item
-
Kimmick, Gretchen, Susan Dent, and Igor Klem. “Risk of Cardiomyopathy in Breast Cancer: How Can We Attenuate the Risk of Heart Failure from Anthracyclines and Anti-HER2 Therapies?” Curr Treat Options Cardiovasc Med 21, no. 6 (May 31, 2019): 30. https://doi.org/10.1007/s11936-019-0736-1.Full Text Link to Item
-
Robertson, Susan J., Mohammed F. K. Ibrahim, Carol Stober, John Hilton, Zuzana Kos, Sasha Mazzarello, Tim Ramsay, et al. “Does integration of Magee equations into routine clinical practice affect whether oncologists order the Oncotype DX test? A prospective randomized trial.” J Eval Clin Pract 25, no. 2 (April 2019): 196–204. https://doi.org/10.1111/jep.13094.Full Text Link to Item
-
Kelly, F., C. Liska, R. Morash, J. Hu, S. L. Carroll, R. Shorr, S. Dent, and D. Stacey. “Shared medical appointments for patients with a nondiabetic physical chronic illness: A systematic review.” Chronic Illn 15, no. 1 (March 2019): 3–26. https://doi.org/10.1177/1742395317731608.Full Text Link to Item
-
Dent, S., C. Ammendolea, A. Christofides, S. Edwards, D. Incekol, B. Pourmirza, S. Kfoury, and B. Poirier. “A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer.” Curr Oncol 26, no. 1 (February 2019): e70–80. https://doi.org/10.3747/co.26.4220.Full Text Link to Item
-
Devi, Gayathri R., Holly Hough, Nadine Barrett, Massimo Cristofanilli, Beth Overmoyer, Neil Spector, Naoto T. Ueno, et al. “Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium.” J Cancer 10, no. 15 (2019): 3344–51. https://doi.org/10.7150/jca.31176.Full Text Open Access Copy Link to Item
-
Le May, M., and S. Dent. “Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration associated with cognitive affective syndrome in a patient with breast cancer: a case report and literature review.” Curr Oncol 25, no. 6 (December 2018): e585–91. https://doi.org/10.3747/co.25.4106.Full Text Link to Item
-
Dang, Chau T., Anne Blaes, Filipa Lynce, Sandra M. Swain, and Susan Dent. “Left Ventricular Ejection Fraction Monitoring Adherence Rates: Why So Low?” Jacc Cardiovasc Imaging 11, no. 8 (August 2018): 1094–97. https://doi.org/10.1016/j.jcmg.2018.02.027.Full Text Link to Item
-
Dent, S. F. “Progress in breast cancer-can we do better?” Curr Oncol 25, no. Suppl 1 (June 2018): S7–8. https://doi.org/10.3747/co.25.4159.Full Text Link to Item
-
Phillips, W. J., C. Johnson, A. Law, M. Turek, A. R. Small, J. R. Inacio, S. Dent, et al. “Reporting of coronary artery calcification on chest CT studies in breast cancer patients at high risk of cancer therapy related cardiac events.” Ijc Heart and Vasculature 18 (March 1, 2018): 12–16. https://doi.org/10.1016/j.ijcha.2018.02.001.Full Text
-
Mehta, Laxmi S., Karol E. Watson, Ana Barac, Theresa M. Beckie, Vera Bittner, Salvador Cruz-Flores, Susan Dent, et al. “Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association.” Circulation 137, no. 8 (February 20, 2018): e30–66. https://doi.org/10.1161/CIR.0000000000000556.Full Text Link to Item
-
Bernstein, V., S. L. Ellard, S. F. Dent, D. Tu, M. Mates, S. K. Dhesy-Thind, L. Panasci, et al. “A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.” Breast Cancer Res Treat 167, no. 2 (January 2018): 485–93. https://doi.org/10.1007/s10549-017-4538-4.Full Text Link to Item
-
Kelly, F., S. L. Carroll, M. Carley, S. Dent, R. Shorr, J. Hu, R. Morash, and D. Stacey. “Symptom practice guide for telephone assessment of patients with cancer treatment-related cardiotoxic dyspnea: Adaptation and evaluation of acceptability.” Cardio Oncology 3, no. 1 (December 1, 2017). https://doi.org/10.1186/s40959-017-0026-6.Full Text
-
Law, W., C. Johnson, M. Rushton, and S. Dent. “The Framingham risk score underestimates the risk of cardiovascular events in the HER2-positive breast cancer population.” Curr Oncol 24, no. 5 (October 2017): e348–53. https://doi.org/10.3747/co.24.3684.Full Text Link to Item
-
Li, Chunze, Priya Agarwal, Ekaterina Gibiansky, Jin Yan Jin, Susan Dent, Anthony Gonçalves, Ihsan Nijem, et al. “A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function.” Clin Pharmacokinet 56, no. 9 (September 2017): 1069–80. https://doi.org/10.1007/s40262-016-0496-y.Full Text Link to Item
-
Rushton, M., C. Johnson, and S. Dent. “Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population.” Curr Oncol 24, no. 3 (June 2017): 176–80. https://doi.org/10.3747/co.24.3349.Full Text Link to Item
-
Armenian, Saro H., Christina Lacchetti, Ana Barac, Joseph Carver, Louis S. Constine, Neelima Denduluri, Susan Dent, et al. “Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.” J Clin Oncol 35, no. 8 (March 10, 2017): 893–911. https://doi.org/10.1200/JCO.2016.70.5400.Full Text Link to Item
-
Lenihan, Daniel J., Susan Dent, and Joseph Carver. “Response: Proposing and Meeting the Need for Interdisciplinary Cardio-Oncology Subspecialty Training by Sherry-Ann Brown, MD, PhD and Nicole Sandhu, MD, PhD.” J Card Fail 22, no. 11 (November 2016): 936. https://doi.org/10.1016/j.cardfail.2016.09.018.Full Text Link to Item
-
Zamorano, Jose Luis, Patrizio Lancellotti, Daniel Rodriguez Muñoz, Victor Aboyans, Riccardo Asteggiano, Maurizio Galderisi, Gilbert Habib, et al. “2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).” Eur Heart J 37, no. 36 (September 21, 2016): 2768–2801. https://doi.org/10.1093/eurheartj/ehw211.Full Text Link to Item
-
Curigliano, Giuseppe, Daniela Cardinale, Susan Dent, Carmen Criscitiello, Olexiy Aseyev, Daniel Lenihan, and Carlo Maria Cipolla. “Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.” Ca Cancer J Clin 66, no. 4 (July 2016): 309–25. https://doi.org/10.3322/caac.21341.Full Text Link to Item
-
Sulpher, Jeffrey, Pierre Giguere, Sean Hopkins, and Susan Dent. “Impact of an electronic tool in prescribing primary prophylaxis with ciprofloxacin or granulocyte colony-stimulating factor for breast cancer patients receiving TC chemotherapy.” Support Care Cancer 24, no. 7 (July 2016): 3185–89. https://doi.org/10.1007/s00520-016-3143-0.Full Text Link to Item
-
Virani, Sean A., Susan Dent, Christine Brezden-Masley, Brian Clarke, Margot K. Davis, Davinder S. Jassal, Christopher Johnson, et al. “Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy.” Can J Cardiol 32, no. 7 (July 2016): 831–41. https://doi.org/10.1016/j.cjca.2016.02.078.Full Text Link to Item
-
Broglio, Kristine R., Melanie Quintana, Margaret Foster, Melissa Olinger, Anna McGlothlin, Scott M. Berry, Jean-François Boileau, et al. “Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis.” Jama Oncol 2, no. 6 (June 1, 2016): 751–60. https://doi.org/10.1001/jamaoncol.2015.6113.Full Text Link to Item
-
Lenihan, Daniel J., Gregory Hartlage, Jeanne DeCara, Anne Blaes, J Emanuel Finet, Alexander R. Lyon, Robert F. Cornell, et al. “Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty.” J Card Fail 22, no. 6 (June 2016): 465–71. https://doi.org/10.1016/j.cardfail.2016.03.012.Full Text Link to Item
-
Rayson, Daniel, Sasha Lupichuk, Kylea Potvin, Susan Dent, Tamara Shenkier, Sukhbinder Dhesy-Thind, Susan L. Ellard, et al. “Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.” Breast Cancer Res Treat 157, no. 1 (May 2016): 109–16. https://doi.org/10.1007/s10549-016-3812-1.Full Text Link to Item
-
Aseyev, O., M. Turek, C. Johnson, F. Crowley, and S. Dent. “Age is a Factor for Referral of Women With Left Ventricular Dysfunction During Trastuzumab-based Treatment for HER2-positive Breast Cancer: Single-center Retrospective Data Analysis.” Canadian Journal of Cardiology 32, no. 4 (April 1, 2016): S8. https://doi.org/10.1016/j.cjca.2016.02.023.Full Text
-
Clemons, Mark, Nathaniel Bouganim, Stephanie Smith, Sasha Mazzarello, Lisa Vandermeer, Roanne Segal, Susan Dent, et al. “Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.” Jama Oncol 2, no. 2 (February 2016): 225–31. https://doi.org/10.1001/jamaoncol.2015.3730.Full Text Link to Item
-
Arnaout, A., I. Kuchuk, N. Bouganim, G. Pond, S. Verma, R. Segal, S. Dent, et al. “Can the referring surgeon enhance accrual of breast cancer patients to medical and radiation oncology trials? The ENHANCE study.” Current Oncology 23, no. 3 (January 1, 2016): e276–79. https://doi.org/10.3747/co.23.2394.Full Text
-
Jacobs, C., I. Kuchuk, N. Bouganim, S. Smith, S. Mazzarello, L. Vandermeer, G. Dranitsaris, et al. “A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.” Breast Cancer Res Treat 155, no. 1 (January 2016): 77–84. https://doi.org/10.1007/s10549-015-3646-2.Full Text Link to Item
-
Rushton, M., F. Crawley, J. Sulpher, C. Johnson, and S. Dent. “Cardiotoxicity in breast cancer patients: A single center, retrospective review.” Progress in Pediatric Cardiology 39, no. 2 (November 1, 2015): 67–69. https://doi.org/10.1016/j.ppedcard.2015.10.002.Full Text
-
Simos, Demetrios, Christina Catley, Carl van Walraven, Angel Arnaout, Christopher M. Booth, Matthew McInnes, Dean Fergusson, Susan Dent, and Mark Clemons. “Imaging for distant metastases in women with early-stage breast cancer: a population-based cohort study.” Cmaj 187, no. 12 (September 8, 2015): E387–97. https://doi.org/10.1503/cmaj.150003.Full Text Link to Item
-
Simmons, Christine, Susan Dent, and Christine Brezden-Masley. “Duration of Trastuzumab. In matters of the heart, one size may not fit all?” Eur J Cancer 51, no. 13 (September 2015): 1657–59. https://doi.org/10.1016/j.ejca.2015.06.004.Full Text Link to Item
-
Gelmon, Karen A., Frances M. Boyle, Bella Kaufman, David G. Huntsman, Alexey Manikhas, Angelo Di Leo, Miguel Martin, et al. “Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.” J Clin Oncol 33, no. 14 (May 10, 2015): 1574–83. https://doi.org/10.1200/JCO.2014.56.9590.Full Text Link to Item
-
Brackstone, M., G. G. Fletcher, I. S. Dayes, Y. Madarnas, S. K. Sen Gupta, S. Verma, A. Eisen, et al. “Locoregional therapy of locally advanced breast cancer: A clinical practice guideline.” Current Oncology 22 (March 1, 2015): S54–66. https://doi.org/10.3747/co.22.2316.Full Text
-
Attard, C. L., A. N. Pepper, S. T. Brown, M. F. Thompson, P. -. O. Thuresson, S. Yunger, S. Dent, A. H. Paterson, and G. A. Wells. “Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.” J Med Econ 18, no. 3 (March 2015): 173–88. https://doi.org/10.3111/13696998.2014.979938.Full Text Link to Item
-
Eisen, A., G. G. Fletcher, S. Gandhi, M. Mates, O. C. Freedman, S. F. Dent, M. E. Trudeau, and M. E. members of the Early Breast Cancer Systemic Therapy Consensus Panel. “Optimal systemic therapy for early breast cancer in women: a clinical practice guideline.” Curr Oncol 22, no. Suppl 1 (March 2015): S67–81. https://doi.org/10.3747/co.22.2320.Full Text Link to Item
-
Enright, Katherine, Eva Grunfeld, Lingsong Yun, Rahim Moineddin, Mohammad Ghannam, Susan Dent, Andrea Eisen, et al. “Population-based assessment of emergency room visits and hospitalizations among women receiving adjuvant chemotherapy for early breast cancer.” J Oncol Pract 11, no. 2 (March 2015): 126–32. https://doi.org/10.1200/JOP.2014.001073.Full Text Link to Item
-
Freedman, O. C., G. G. Fletcher, S. Gandhi, M. Mates, S. F. Dent, M. E. Trudeau, and A. Eisen. “Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.” Curr Oncol 22, no. Suppl 1 (March 2015): S95–113. https://doi.org/10.3747/co.22.2326.Full Text Link to Item
-
Gandhi, S., G. G. Fletcher, A. Eisen, M. Mates, O. C. Freedman, S. F. Dent, and M. E. Trudeau. “Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.” Curr Oncol 22, no. Suppl 1 (March 2015): S82–94. https://doi.org/10.3747/co.22.2321.Full Text Link to Item
-
Mates, M., G. G. Fletcher, O. C. Freedman, A. Eisen, S. Gandhi, M. E. Trudeau, and S. F. Dent. “Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.” Curr Oncol 22, no. Suppl 1 (March 2015): S114–22. https://doi.org/10.3747/co.22.2322.Full Text Link to Item
-
Chia, S., S. Gandhi, A. A. Joy, S. Edwards, M. Gorr, S. Hopkins, J. Kondejewski, et al. “Novel agents and associated toxicities of inhibitors of the PI3k/Akt/mtor pathway for the treatment of breast cancer.” Current Oncology 22, no. 1 (January 1, 2015): 33–48. https://doi.org/10.3747/co.22.2393.Full Text
-
Dent, S., P. Liu, C. Brezden-Masley, and D. Lenihan. “Cancer and Cardiovascular Disease: The Complex Labyrinth.” Journal of Oncology 2015 (January 1, 2015). https://doi.org/10.1155/2015/516450.Full Text
-
Sulpher, J., S. Mathur, D. Lenihan, C. Johnson, M. Turek, A. Law, E. Stadnick, F. Dattilo, N. Graham, and S. F. Dent. “An International Survey of Health Care Providers Involved in the Management of Cancer Patients Exposed to Cardiotoxic Therapy.” Journal of Oncology 2015 (January 1, 2015). https://doi.org/10.1155/2015/391848.Full Text
-
Sulpher, J., S. Mathur, N. Graham, F. Crawley, M. Turek, C. Johnson, E. Stadnick, A. Law, J. Wentzell, and S. Dent. “Clinical Experience of Patients Referred to a Multidisciplinary Cardiac Oncology Clinic: An Observational Study.” Journal of Oncology 2015 (January 1, 2015). https://doi.org/10.1155/2015/671232.Full Text
-
Zhu, Xiaofu, Susan Dent, Lise Paquet, Tinghua Zhang, Nadine Graham, and Xinni Song. “Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.” Eur J Cancer 50, no. 15 (October 2014): 2544–49. https://doi.org/10.1016/j.ejca.2014.07.010.Full Text Link to Item
-
Addison, Christina L., Nathaniel Bouganim, John Hilton, Lisa Vandermeer, Susan Dent, Eitan Amir, Sean Hopkins, et al. “A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.” Breast Cancer Research and Treatment 144, no. 3 (April 2014): 615–24. https://doi.org/10.1007/s10549-014-2906-x.Full Text
-
Sulpher, Jeffrey, Rebecca Dent, and Susan Dent. “Neoadjuvant chemotherapy in breast cancer: what questions remain?” Curr Opin Support Palliat Care 8, no. 1 (March 2014): 59–63. https://doi.org/10.1097/SPC.0000000000000033.Full Text Link to Item
-
Beusterien, Kathleen, Jessica Grinspan, Iryna Kuchuk, Sasha Mazzarello, Susan Dent, Stan Gertler, Nathaniel Bouganim, Lisa Vandermeer, and Mark Clemons. “Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects.” The Oncologist 19, no. 2 (February 2014): 127–34. https://doi.org/10.1634/theoncologist.2013-0359.Full Text
-
Chapman, J. A. W., K. I. Pritchard, P. E. Goss, J. N. Ingle, H. B. Muss, S. F. Dent, T. A. Vandenberg, et al. “Competing risks of death in younger and older postmenopausal breast cancer patients.” World Journal of Clinical Oncology 5, no. 5 (January 1, 2014): 1088–96. https://doi.org/10.5306/wjco.v5.i5.1088.Full Text
-
Khalaf, D., J. F. Hilton, M. Clemons, L. Azoulay, H. Yin, L. Vandermeer, S. Dent, S. Hopkins, and N. Bouganim. “Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression.” Oncology Letters 7, no. 3 (January 1, 2014): 866–70. https://doi.org/10.3892/ol.2014.1782.Full Text
-
Rushton, M., A. Kwong, H. Visram, N. Graham, W. Petrcich, and S. Dent. “Treatment outcomes for male breast cancer: A single-centre retrospective case-control study.” Current Oncology 21, no. 3 (January 1, 2014): 400–407. https://doi.org/10.3747/co.21.1730.Full Text
-
Sulpher, J., C. Johnson, M. Turek, A. Law, E. Stadnick, S. Hopkins, N. Graham, and S. F. Dent. “Ottawa cardiac oncology program wins 2013 cancer: Quality council of ontario innovation award.” Current Oncology 21, no. 3 (January 1, 2014): 150. https://doi.org/10.3747/co.21.1913.Full Text
-
Dent, S. F., K. A. Gelmon, K. N. Chi, D. J. Jonker, N. Wainman, C. A. Capier, E. X. Chen, J. F. Lyons, and L. Seymour. “NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies.” Invest New Drugs 31, no. 6 (December 2013): 1522–29. https://doi.org/10.1007/s10637-013-0018-9.Full Text Link to Item
-
Kuchuk, I., N. Bouganim, K. Beusterien, J. Grinspan, L. Vandermeer, S. Gertler, S. F. Dent, et al. “Preference weights for chemotherapy side effects from the perspective of women with breast cancer.” Breast Cancer Res Treat 142, no. 1 (November 2013): 101–7. https://doi.org/10.1007/s10549-013-2727-3.Full Text Link to Item
-
Dent, Susan, Basak Oyan, Arnd Honig, Max Mano, and Sacha Howell. “HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials.” Cancer Treat Rev 39, no. 6 (October 2013): 622–31. https://doi.org/10.1016/j.ctrv.2013.01.002.Full Text Link to Item
-
Frechette, Dominique, Lise Paquet, Shailendra Verma, Mark Clemons, Paul Wheatley-Price, Stan Z. Gertler, Xinni Song, Nadine Graham, and Susan Dent. “The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study.” Breast Cancer Res Treat 141, no. 1 (August 2013): 111–17. https://doi.org/10.1007/s10549-013-2659-y.Full Text Link to Item
-
Dranitsaris, George, Nathaniel Bouganim, Carolyn Milano, Lisa Vandermeer, Susan Dent, Paul Wheatley-Price, Jenny Laporte, Karen-Ann Oxborough, and Mark Clemons. “Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting.” The Journal of Supportive Oncology 11, no. 1 (March 2013): 14–21. https://doi.org/10.1016/j.suponc.2012.05.001.Full Text
-
Dent, S., J. Fraser, N. Graham, M. Campbell, S. Hopkins, and G. Dranitsaris. “Clinical outcomes of women with metastatic breast cancer treated with nab-paclitaxel: Experience from a single academic cancer centre.” Current Oncology 20, no. 1 (January 1, 2013): 24–29. https://doi.org/10.3747/co.20.1202.Full Text
-
Dent, S., S. Hopkins, N. Graham, C. Johnson, A. Law, M. Campbell, F. Crawley, K. Allen, and M. Turek. “The experience of a multidisciplinary clinic in the management of early-stage breast cancer patients receiving trastuzumab therapy: An observational study.” Cardiology Research and Practice 1, no. 1 (December 1, 2012). https://doi.org/10.1155/2012/135819.Full Text
-
Bouganim, N., G. Dranitsaris, S. Hopkins, L. Vandermeer, L. Godbout, S. Dent, P. Wheatley-Price, C. Milano, and M. Clemons. “Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting.” Current Oncology 19, no. 6 (January 1, 2012). https://doi.org/10.3747/co.19.1074.Full Text
-
Samiee, S., P. Berardi, N. Bouganim, L. Vandermeer, A. Arnaout, S. Dent, D. Mirsky, M. Chasen, J. M. Caudrelier, and M. Clemons. “Excision of the primary tumour in patients with metastatic breast cancer: A clinical dilemma.” Current Oncology 19, no. 4 (January 1, 2012). https://doi.org/10.3747/co.19.974.Full Text
-
Zhu, X., N. Bouganim, L. Vandermeer, S. F. Dent, G. Dranitsaris, and M. J. Clemons. “Use and delivery of granulocyte colony-stimulating factor in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy-single-centre experience.” Current Oncology 19, no. 4 (January 1, 2012). https://doi.org/10.3747/co.19.948.Full Text
-
Grunfeld, Eva, Jim A. Julian, Gregory Pond, Elizabeth Maunsell, Douglas Coyle, Amy Folkes, Anil A. Joy, et al. “Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer.” J Clin Oncol 29, no. 36 (December 20, 2011): 4755–62. https://doi.org/10.1200/JCO.2011.36.8373.Full Text Link to Item
-
Pritchard, Kathleen I., Lois E. Shepherd, Judith-Anne W. Chapman, Brian D. Norris, Jacques Cantin, Paul E. Goss, Susan F. Dent, et al. “Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.” J Clin Oncol 29, no. 29 (October 10, 2011): 3869–76. https://doi.org/10.1200/JCO.2010.33.7006.Full Text Link to Item
-
Hilton, J. F., E. Amir, S. Hopkins, M. Nabavi, G. DiPrimio, A. Sheikh, S. J. Done, et al. “Acquisition of metastatic tissue from patients with bone metastases from breast cancer.” Breast Cancer Res Treat 129, no. 3 (October 2011): 761–65. https://doi.org/10.1007/s10549-010-1264-6.Full Text Link to Item
-
Dent, Susan F., Rania Gaspo, Michelle Kissner, and Kathleen I. Pritchard. “Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer.” Breast Cancer Res Treat 126, no. 2 (April 2011): 295–310. https://doi.org/10.1007/s10549-011-1351-3.Full Text Link to Item
-
Dent, S. F., and N. A. Graham. “First annual Canadian cardiac oncology network conference.” Current Oncology 18, no. 6 (January 1, 2011): 295–300. https://doi.org/10.3747/co.v18i6.968.Full Text
-
Madarnas, Y., S. F. Dent, S. F. Husain, A. Robinson, S. Alkhayyat, W. M. Hopman, J. L. Verreault, and T. Vandenberg. “Real-world experience with adjuvant FEC-D chemotherapy in four Ontario regional cancer centres.” Current Oncology 18, no. 3 (January 1, 2011): 119–25. https://doi.org/10.3747/co.v18i3.751.Full Text
-
Dent, Susan F., Stan Gertler, Shailendra Verma, Roanne Segal, Vince Young, Rakesh Goel, Oliver Keller, Christina Canil, and Neill Iscoe. “A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer.” Cancer Chemother Pharmacol 65, no. 3 (February 2010): 557–61. https://doi.org/10.1007/s00280-009-1064-z.Full Text Link to Item
-
Wong, Nan Soon, Robert A. Buckman, Mark Clemons, Shailendra Verma, Susan Dent, Maureen E. Trudeau, Kathie Roche, et al. “Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 28, no. 5 (February 2010): 723–30. https://doi.org/10.1200/jco.2009.24.0143.Full Text
-
Taylor, Sara K., Stephen Chia, Susan Dent, Mark Clemons, Mark Agulnik, Pamela Grenci, Lisa Wang, et al. “A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.” Oncologist 15, no. 8 (2010): 810–18. https://doi.org/10.1634/theoncologist.2010-0081.Full Text Link to Item
-
Verma, S., S. Lavasani, J. Mackey, K. Pritchard, M. Clemons, S. Dent, J. Latreille, et al. “Optimizing the management of her2-positive early breast cancer: The clinical reality.” Current Oncology 17, no. 4 (January 1, 2010): 20–33. https://doi.org/10.3747/co.v17i4.700.Full Text
-
Visram, H., F. Kanji, and S. F. Dent. “Endocrine therapy for male breast cancer: Rates of toxicity and adherence.” Current Oncology 17, no. 5 (January 1, 2010): 17–21. https://doi.org/10.3747/co.v17i5.631.Full Text
-
Freedman, Orit, Eitan Amir, George Dranitsaris, Julie Napolskikh, Ritu Kumar, Michael Fralick, Stephen Chia, et al. “Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients.” Breast Cancer Res Treat 118, no. 2 (November 2009): 377–83. https://doi.org/10.1007/s10549-009-0452-8.Full Text Link to Item
-
Dent, S. F. “The role of VEGF in triple-negative breast cancer: where do we go from here?” Ann Oncol 20, no. 10 (October 2009): 1615–17. https://doi.org/10.1093/annonc/mdp410.Full Text Link to Item
-
Chia, Stephen, Susan Dent, Susan Ellard, Peter M. Ellis, Ted Vandenberg, Karen Gelmon, Jean Powers, Wendy Walsh, Lesley Seymour, and Elizabeth A. Eisenhauer. “Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer.” Clin Cancer Res 15, no. 2 (January 15, 2009): 708–13. https://doi.org/10.1158/1078-0432.CCR-08-1159.Full Text Link to Item
-
Dent, S., S. Verma, J. Latreille, D. Rayson, M. Clemons, J. Mackey, J. Lemieux, et al. “The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer.” Current Oncology 16, no. 4 (January 1, 2009): 25–35. https://doi.org/10.3747/co.v16i4.469.Full Text
-
Lemieux, J., M. Clemons, L. Provencher, S. Dent, J. Latreille, J. Mackey, K. I. Pritchard, et al. “The role of neoadjuvant HER2-targeted therapies in HER2-overexpressing breast cancers.” Current Oncology 16, no. 5 (January 1, 2009): 48–57. https://doi.org/10.3747/co.v16i5.510.Full Text
-
Verma, Shailendra, Susan Dent, Benjamin J. W. Chow, Daniel Rayson, and Tamar Safra. “Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines.” Cancer Treat Rev 34, no. 5 (August 2008): 391–406. https://doi.org/10.1016/j.ctrv.2008.01.008.Full Text Link to Item
-
Grunfeld, Eva, Robin Urquhart, Eric Mykhalovskiy, Amy Folkes, Grace Johnston, Frederick I. Burge, Craig C. Earle, and Susan Dent. “Toward population-based indicators of quality end-of-life care: testing stakeholder agreement.” Cancer 112, no. 10 (May 15, 2008): 2301–8. https://doi.org/10.1002/cncr.23428.Full Text Link to Item
-
Dent, Susan, Hans Messersmith, and Maureen Trudeau. “Gemcitabine in the management of metastatic breast cancer: a systematic review.” Breast Cancer Res Treat 108, no. 3 (April 2008): 319–31. https://doi.org/10.1007/s10549-007-9610-z.Full Text Link to Item
-
Saginur, Raphael, Susan F. Dent, Lisa Schwartz, Ronald Heslegrave, Sid Stacey, and Janet Manzo. “Ontario Cancer Research Ethics Board: lessons learned from developing a multicenter regional institutional review board.” J Clin Oncol 26, no. 9 (March 20, 2008): 1479–82. https://doi.org/10.1200/JCO.2007.12.6441.Full Text Link to Item
-
Leighl, Natasha B., Susan Dent, Mark Clemons, Theodore A. Vandenberg, Richard Tozer, David G. Warr, R Michael Crump, et al. “A Phase 2 study of perifosine in advanced or metastatic breast cancer.” Breast Cancer Research and Treatment 108, no. 1 (March 2008): 87–92. https://doi.org/10.1007/s10549-007-9584-x.Full Text
-
Mackey, J. R., M. Clemons, M. A. Côté, D. Delgado, S. Dent, A. Paterson, L. Provencher, M. B. Sawyer, and S. Verma. “Cardiac management during adjuvant trastuzumab therapy: Recommendations of the Canadian Trastuzumab Working Group.” Current Oncology 15, no. 1 (January 1, 2008): 24–35. https://doi.org/10.3747/co.2008.199.Full Text
-
Grunfeld, Eva, Mark N. Levine, Jim A. Julian, Doug Coyle, Barbara Szechtman, Doug Mirsky, Shailendara Verma, et al. “Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care.” J Clin Oncol 24, no. 6 (February 20, 2006): 848–55. https://doi.org/10.1200/JCO.2005.03.2235.Full Text Link to Item
-
Bjarnason, Georg A., Danielle Charpentier, Ralph Wong, Rakesh Goel, Lynn Douglas, Wendy Walsh, Sarah Matthews, Susan Dent, Lesley Seymour, and Eric Winquist. “Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98).” Invest New Drugs 23, no. 1 (January 2005): 51–56. https://doi.org/10.1023/B:DRUG.0000047105.38511.2a.Full Text Link to Item
-
Dent, S. F., A. Arnold, D. J. Stewart, S. Gertler, J. Ayoub, G. Batist, G. Goss, et al. “Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small-cell lung cancer.” Lung 183, no. 4 (2005): 265–72. https://doi.org/10.1007/s00408-004-2539-7.Full Text Link to Item
-
Reyno, L., L. Seymour, D. Tu, S. Dent, K. Gelmon, B. Walley, A. Pluzanska, et al. “Phase III study of N, N-Diethyl-2-[4-(Phenylmethyl) Phenoxyl] Ethanamine (BMS-2173801-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA-19.” Women’S Oncology Review 4, no. 2 (June 1, 2004): 133–34. https://doi.org/10.1080/14733400410001728456.Full Text
-
Reyno, Leonard, Lesley Seymour, Dongsheng Tu, Susan Dent, Karen Gelmon, Barbara Walley, Anna Pluzanska, et al. “Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19.” J Clin Oncol 22, no. 2 (January 15, 2004): 269–76. https://doi.org/10.1200/JCO.2003.04.075.Full Text Link to Item
-
Whelan, Timothy, Carol Sawka, Mark Levine, Amiram Gafni, Leonard Reyno, Andrew Willan, Jim Julian, et al. “Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer.” J Natl Cancer Inst 95, no. 8 (April 16, 2003): 581–87. https://doi.org/10.1093/jnci/95.8.581.Full Text Link to Item
-
Dent, S., B. Zee, J. Dancey, A. Hanauske, J. Wanders, and E. Eisenhauer. “Application of a new multinomial phase II stopping rule using response and early progression.” J Clin Oncol 19, no. 3 (February 1, 2001): 785–91. https://doi.org/10.1200/JCO.2001.19.3.785.Full Text Link to Item
-
Dent, S. F., D. Klaassen, J. L. Pater, B. Zee, and M. Whitehead. “Second primary malignancies following the treatment of early stage ovarian cancer: update of a study by the National Cancer Institute of Canada--Clinical Trials Group (NCIC-CTG).” Ann Oncol 11, no. 1 (January 2000): 65–68. https://doi.org/10.1023/a:1008356806417.Full Text Link to Item
-
Khoo, K., L. Brandes, L. Reyno, A. Arnold, S. Dent, T. Vandenberg, D. Lebwohl, B. Fisher, and E. Eisenhauer. “Phase II trial of N,N-diethyl,2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and doxorubicin chemotherapy in metastatic breast cancer: A National Cancer Institute of Canada Clinical Trials Group study.” Journal of Clinical Oncology 17, no. 11 (January 1, 1999): 3431–37. https://doi.org/10.1200/JCO.1999.17.11.3431.Full Text
-
Dent, S. F., and E. A. Eisenhauer. “Phase I trial design: are new methodologies being put into practice?” Ann Oncol 7, no. 6 (August 1996): 561–66. https://doi.org/10.1093/oxfordjournals.annonc.a010671.Full Text Link to Item
-
Dent, S., L. Eapen, A. Girard, H. Hugenholtz, V. DaSilva, and D. J. Stewart. “PROMACE-MOPP and intrathecal chemotherapy for CNS lymphomas.” J Neurooncol 28, no. 1 (April 1996): 25–30. https://doi.org/10.1007/BF00300443.Full Text Link to Item
-
-
Book Sections
-
Khouri, M. G., I. Klem, C. Shenoy, J. Sulpher, and S. F. Dent. “Screening and monitoring for cardiotoxicity during cancer treatment.” In Cardio-Oncology: The Clinical Overlap of Cancer and Heart Disease, 43–80, 2017. https://doi.org/10.1007/978-3-319-43096-6_3.Full Text
-
Dent, S., A. Law, O. Aseyev, N. Ghosh, and C. Johnson. “Coordinating Cardio-Oncology Care.” In Cardio-Oncology: Principles, Prevention and Management, 221–36, 2017. https://doi.org/10.1016/B978-0-12-803547-4.00015-X.Full Text
-
Barac, A., R. O’Quinn, S. Dent, O. Aseyev, and J. R. Carver. “Cardio-oncology Fellowship Programs.” In Clinical Cardio-Oncology, 445–52, 2016. https://doi.org/10.1016/B978-0-323-44227-5.00023-5.Full Text
-
-
Conference Papers
-
Dent, Susan Faye, Henning Steen, Moritz Montenbruck, Sebastian Esch, Pia Wulfing, Kyle Janson, and Daniel Lenihan. “Abstract P5-14-18: Cardioprotective therapy in breast cancer patients with subclinical and clinical cardiotoxicty.” In Cancer Research, Vol. 80. American Association for Cancer Research (AACR), 2020. https://doi.org/10.1158/1538-7445.sabcs19-p5-14-18.Full Text
-
Rushton-Marovac, Moira K., Isac Lima, Meltem Tuna, Chiara Melloni, Kathy Pritchard, Steven Hawken, and Susan F. Dent. “Abstract P5-14-11: Cardiac monitoring in advanced breast cancer patients treated with trastuzumab: Does it improve cardiac safety?” In Cancer Research, Vol. 80. American Association for Cancer Research (AACR), 2020. https://doi.org/10.1158/1538-7445.sabcs19-p5-14-11.Full Text
-
Melloni, Chiara, Gretchen G. Kimmick, Taofik Oyekunle, Leah L. Zullig, Michel G. Khouri, Lauren Howard, Michael J. Kelley, and Susan F. Dent. “Statin Use is Associated With Increased Overall Survival in Patients With Colorectal Cancer: Findings From a Cohort of 29,498 United States Veterans.” In Circulation, Vol. 140, 2019.Link to Item
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.